What happens to Sinovac, the Chinese Covid vaccine company that flopped in Brazil
Facts, names, numbers and curiosities about Sinovac, the Chinese company that has suspended the testing of the anti Covid vaccine in Brazil
Brazil has suspended the phase III trial of China's Sinovac's CoronaVac vaccine. But the Beijing-based company, led by Weidong Yin, argues that the drug is safe and that the adverse reaction is not related to the vaccine.
All the details.
THE SUSPENSION
Anvisa, the Brazilian health authority, has suspended clinical studies of the anti-Covid vaccine developed by Sinovac due to a serious "accident" involving a volunteer.
Anvisa, explains the same Authority, has "decided to stop the clinical trial of the CoronaVac vaccine after a serious adverse accident" which took place on 29 October.
FATAL SIDE EFFECTS
Without giving any details that could harm the privacy of the people involved, Anvisa also announced that the adverse reaction could lead to accidents that included potentially fatal side effects, severe disability, hospitalization, birth defects and other "clinically significant events".
SINOVAC: INCIDENT NOT RELATED TO VACCINE
For Sinovac, who learned the news from the media, the incident "is not related to the vaccine."
"The clinical trial in Brazil is strictly conducted in accordance with GCP requirements and we are confident in the safety of the vaccine," the company said in a statement.
WHO IS SINOVAC (AND WHAT IT HAS DONE)
Founded in 1993, Sinovac focuses on the research, development, production and marketing of vaccines for human and animal use. The company also provides disease control and prevention services by partnering with Chinese governments at the national, state and local levels. Sinovac has successfully developed the hepatitis A vaccine.
"Over the past two decades, the company has developed and marketed six vaccines for human use and one vaccine for animals," the site reads, specifying that it also developed the world's first H1N1 vaccine in 2009.
THE MANAGEMENT
Leading the Chinese company is Weidong Yin, president and CEO of Sinovac Biotech Ltd. since September 2003. Yin, explains Sinovac, is also the company's general manager, as well as president of Sinovac Hong Kong, Tangshan Yian and Sinovac Dalian. Previously he worked as an infectious disease specialist at the China Center for Disease Control and Prevention in Tangshan City, Hebei Province.
THE NUMBERS
The Chinese company recorded, in 2018, a net profit of 36,111 thousand US dollars , for an adjusted Ebitda of 54,757 US dollars.
This is a machine translation from Italian language of a post published on Start Magazine at the URL https://www.startmag.it/sanita/cosa-succede-a-sinovac-la-societa-cinese-del-vaccino-anti-covid-che-ha-fatto-flop-in-brasile/ on Tue, 10 Nov 2020 14:00:00 +0000.